lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
=== August === 1 August – A study in Nature finds that based on current policies, there is a 45% risk of at least one major tipping point by 2300, even if global warming is brought back to below 1.5 °C. The risk is "strongly accelerated" for peak warming above 2.0 °C. The Atlantic Meridional Overturning Current (AMOC) is identified as being at the most urgent risk of collapse – possibly occurring as early as 2040 – followed by the Amazon rainforest in the 2070s. 5 August A study indicates vegetarian and vegan dog diets are healthier than both conventional meat and raw meat diets according to indicators like numbers of veterinary visits and reported veterinary assessment of being unwell, consistent with all related studies published to date. An analysis suggests hydraulic lifts may have been used to build ancient large Egyptian pyramids. 7 August – Scientists in Australia publish a new 400-year temperature reconstruction for the Coral Sea, showing that recent ocean heat has led to mass bleaching on the Great Barrier Reef. 8 August – A study on the terraforming of Mars suggests that releasing metal nanorods into the planet's atmosphere could warm it by 30 K, and would be far more efficient than trying to do so with greenhouse gases. 12 August Liquid water is confirmed to be present at depths of 10 to 20 km (6.2 to 12.4 mi) below the surface of Mars, based on a new analysis of data from NASA's InSight lander. An Earth-sized, ultra-short period exoplanet called TOI-6255b is found to be undergoing extreme tidal distortion, caused by the close proximity of its parent star.
== Other aspects and examples == In the CCS system, carbon chain lengths are denoted by celestial stems (甲 jiǎ, 乙 yǐ, 丙 bǐng, 丁 dīng, 戊 wù, 己 jǐ, 庚 gēng, 辛 xīn, 壬 rén, 癸 guǐ), characters used since the Shang dynasty (16th–11th centuries BCE) for naming days (and later, to name years). For example, hexane is 己烷 jǐwán, since 己 jǐ is the sixth celestial stem. Longer carbon chains are specified by number followed by '碳' tàn 'carbon'. For example, 1-hexadecene is 1-十六碳烯 (read as [1, yī] [-, wèi] [十六, shíliù, '16'] [碳, tàn] [烯, xī]), where the hyphen is read as 位 (wèi, 'position'). For a more complex example, consider 3-buten-1-ol. Its Chinese name is 3-丁烯-1-醇 (read as [3, sān] [-, wèi] [丁, dīng] [烯, xī] [1, yī] [-, wèi] [醇, chún]). The descriptors for degree of substitution, primary, secondary, tertiary, and quaternary, are translated as 伯 (bó), 仲 (zhòng), 叔 (shū), 季 (jì), which refer to the first, second, third, and fourth male siblings in a family. For instance, tert-butyllithium is translated as 叔丁基锂 ([叔, shū, 'tert'], [丁, dīng, 'but-'], [基, jī, 'yl'], [锂, lǐ, 'lithium']). Other commonly used isomeric descriptors normal-, iso-, and neo- are translated as 正 (zhèng, 'proper'), 异 (yì, 'different'), and 新 (xīn, 'new'), respectively. The numerical prefix bis- is translated as 双 (shuāng, 'double'), while larger multiplicities are simply given by the Chinese word for the number (e.g., 四 (sì, 'four') for tetrakis-). For example, tetrakis(triphenylphosphine)palladium is rendered 四(三苯基膦)钯, in which 三苯基膦 is triphenylphosphine and 钯 is palladium.
Tachykinin peptides are also involved in inflammation, and tachykinin receptor antagonists have been researched for use in treating inflammatory conditions such as asthma and irritable bowel syndrome. The main use for which these antagonist drugs have been applied so far, however, is as antiemetics, in both human and veterinary medicine. Examples of tachykinin antagonists include:
Sources: en.wikipedia.org
=== Post-war === The division suffered 995 killed and 7,082 wounded, for a total of 8,077 casualties. Following the war's end, the division moved to training areas near Prauthoy, where it remained to February 1919. It returned to the United States in April and May, and was demobilized and deactivated at Camp Mills, New York, on 27 May.
Selenium at The Periodic Table of Videos (University of Nottingham) National Institutes of Health page on Selenium Assay Archived 2012-02-26 at the Wayback Machine ATSDR – Toxicological Profile: Selenium CDC – NIOSH Pocket Guide to Chemical Hazards Peter van der Krogt elements site
=== Brand names === It is sold under the brand names Heartgard, Sklice, and Stromectol in the United States, Ivomec worldwide by Merial Animal Health, Mectizan in Canada by Merck, Iver-DT in Nepal by Alive Pharmaceutical and Ivexterm in Mexico by Valeant Pharmaceuticals International. In Southeast Asian countries, it is marketed by Delta Pharma Ltd. under the trade name Scabo 6. The formulation for rosacea treatment is sold under the brand name Soolantra. While in development, it was assigned the code MK-933 by Merck.
Sources: en.wikipedia.org
== History == In 1822 the first awards were given to thirteen people by the Philadelphia Society for Promoting Agriculture entrusted by the "Corporation of the city of Philadelphia". The druggist John Scott of Edinburgh organized a $4,000 fund which, after his death in 1815 was administered by a merchant until the first award, a copper medal and "an amount not to exceed twenty dollars", was given in 1822. (At the time, $20 could buy one ox or a 12-volume encyclopedia.) Several hundred recipients have since been selected by the City Council of Philadelphia, which decides from the annual list of nominees made by the Franklin Institute.
==== Hypopharyngeal or base of tongue obstruction ==== Base-of-tongue advancement by means of advancing the genial tubercle of the mandible, tongue suspension, or hyoid suspension (aka hyoid myotomy and suspension or hyoid advancement) may help with the lower pharynx. Other surgery options may attempt to shrink or stiffen excess tissue in the mouth or throat, procedures done at either a doctor's office or a hospital. Small shots or other treatments, sometimes in a series, are used for shrinkage, while the insertion of a small piece of stiff plastic is used in the case of surgery whose goal is to stiffen tissues.
== Pharmacology == Akuammine has antimalarial activity, and may be the primary constituent of P. nitida seeds responsible for this activity. Akuammine is an opioid agonist with low affinity, selective for the mu-opioid receptor, when tested in vitro.
Fourteen distinct types are available in addition to botanical tulips, including Lily-flowered, Fringed, Viridiflora, and Rembrandt. In addition to blooming season, tulip varieties differ in shape and height, and exhibit a wide range of colours, both pure and in combination.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.